Search Results - "Maris, B."

Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation by Sorror, Mohamed L, Storb, Rainer F, Sandmaier, Brenda M, Maziarz, Richard T, Pulsipher, Michael A, Maris, Michael B, Bhatia, Smita, Ostronoff, Fabiana, Deeg, H Joachim, Syrjala, Karen L, Estey, Elihu, Maloney, David G, Appelbaum, Frederick R, Martin, Paul J, Storer, Barry E

“…Age has long been used as a major factor for assessing suitability for allogeneic hematopoietic cell transplantation (HCT). The HCT-comorbidity index (HCT-CI)…”
Get full text

Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT by Sorror, Mohamed L., Maris, Michael B., Storb, Rainer, Baron, Frederic, Sandmaier, Brenda M., Maloney, David G., Storer, Barry

“…We previously reported that the Charlson Comorbidity Index (CCI) was useful for predicting outcomes in patients undergoing allogeneic hematopoietic cell…”
Get full text

Long-term Outcomes Among Older Patients Following Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation for Advanced Hematologic Malignancies by Sorror, Mohamed L, Sandmaier, Brenda M, Storer, Barry E, Franke, Georg N, Laport, Ginna G, Chauncey, Thomas R, Agura, Edward, Maziarz, Richard T, Langston, Amelia, Hari, Parameswaran, Pulsipher, Michael A, Bethge, Wolfgang, Sahebi, Firoozeh, Bruno, Benedetto, Maris, Michael B, Yeager, Andrew, Petersen, Finn Bo, Vindeløv, Lars, McSweeney, Peter A, Hübel, Kai, Mielcarek, Marco, Georges, George E, Niederwieser, Dietger, Blume, Karl G, Maloney, David G, Storb, Rainer

“…CONTEXT A minimally toxic nonmyeloablative regimen was developed for allogeneic hematopoietic cell transplantation (HCT) to treat patients with advanced…”
Get full text

Graft-Versus-Host Disease and Graft-Versus-Tumor Effects After Allogeneic Hematopoietic Cell Transplantation by Storb, Rainer, Gyurkocza, Boglarka, Storer, Barry E, Sorror, Mohamed L, Blume, Karl, Niederwieser, Dietger, Chauncey, Thomas R, Pulsipher, Michael A, Petersen, Finn B, Sahebi, Firoozeh, Agura, Edward D, Hari, Parameswaran, Bruno, Benedetto, McSweeney, Peter A, Maris, Michael B, Maziarz, Richard T, Langston, Amelia A, Bethge, Wolfgang, Vindeløv, Lars, Franke, Georg-Nikolaus, Laport, Ginna G, Yeager, Andrew M, Hübel, Kai, Deeg, H Joachim, Georges, George E, Flowers, Mary E D, Martin, Paul J, Mielcarek, Marco, Woolfrey, Ann E, Maloney, David G, Sandmaier, Brenda M

“…We designed a minimal-intensity conditioning regimen for allogeneic hematopoietic cell transplantation (HCT) in patients with advanced hematologic malignancies…”
Get full text

Graft-Versus-Tumor Effects After Allogeneic Hematopoietic Cell Transplantation With Nonmyeloablative Conditioning by BARON, Frédéric, MARIS, Michael B, MALONEY, David G, STORB, Rainer, SANDMAIER, Brenda M, STORER, Barry E, SORROR, Mohamed, DIACONESCU, Razvan, WOOLFREY, Ann E, CHAUNCEY, Thomas R, FLOWERS, Mary E. D, MIELCAREK, Marco

“…We have used a nonmyeloablative conditioning regimen consisting of total-body irradiation (2 Gy) with or without fludarabine (30 mg/m(2)/d for 3 days) for…”
Get full text

Pretransplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality by Sorror, Mohamed L., Martin, Paul J., Storb, Rainer F., Bhatia, Smita, Maziarz, Richard T., Pulsipher, Michael A., Maris, Michael B., Davis, Christopher, Deeg, H. Joachim, Lee, Stephanie J., Maloney, David G., Sandmaier, Brenda M., Appelbaum, Frederick R., Gooley, Theodore A.

“…Whether the hematopoietic cell transplantation comorbidity index (HCT-CI) can provide prognostic information about development of acute graft-versus-host…”
Get full text

Comorbidity and Disease Status–Based Risk Stratification of Outcomes Among Patients With Acute Myeloid Leukemia or Myelodysplasia Receiving Allogeneic Hematopoietic Cell Transplantation by SORROR, Mohamed L, SANDMAIER, Brenda M, STORER, Barry E, MARIS, Michael B, BARON, Frederic, MALONEY, David G, SCOTT, Bart L, JOACHIM DEEG, H, APPELBAUM, Frederick R, STORB, Rainer

“…Retrospective studies have shown similar survival among patients with acute myeloid leukemia (AML) and myelodysplasia (MDS) after nonmyeloablative compared…”
Get full text

Reconceptualizing coastal fisheries conflicts: a Swedish case study by Arias Schreiber, Milena, Gillette, Maris B.

“…Fisheries conflicts have often been interpreted as arising from disputes over access to fish. Competition for fishing stocks among resource users (human and…”
Get full text

Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia by GYURKOCZA, Boglarka, STORB, Rainer, BRUNO, Benedetto, PETERSEN, Finn B, MARIS, Michael B, AGURA, Edward, YEAGER, Andrew, BETHGE, Wolfgang, SAHEBI, Firoozeh, APPELBAUM, Frederick R, MALONEY, David G, SANDMAIER, Brenda M, STORER, Barry E, CHAUNCEY, Thomas R, LANGE, Thoralf, SHIZURU, Judith A, LANGSTON, Amelia A, PULSIPHER, Michael A, BREDESON, Christopher N, MAZIARZ, Richard T

“…Allogeneic hematopoietic cell transplantation (HCT) after high-dose conditioning regimens imposes prohibitively high risks of morbidity and mortality for…”
Get full text

Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: Improved outcomes over two decades by Cooper, Jason P, Storer, Barry E, Granot, Noa, Gyurkocza, Boglark, Sorror, Mohamed L, Chauncey, Thomas R, Shizuru, Judith, Franke, Georg-Nikolaus, Maris, Michael B, Boyer, Michael, Bruno, Benedetto, Sahebi, Firoozeh, Langston, Amelia A, Hari, Parameswaran, Agura, Edward D, Lykke Petersen, Søren, Maziarz, Richard T, Bethge, Wolfgang, Asch, Julie, Gutman, Jonathan A, Olesen, Gitte, Yeager, Andrew M, Hübel, Kai, Hogan, William J, Maloney, David G, Mielcarek, Marco, Martin, Paul J, Flowers, Mary E D, Georges, George E, Woolfrey, Ann E, Deeg, Joachim H, Scott, Bart L, McDonald, George B, Storb, Rainer, Sandmaier, Brenda M

“…We have used a non-myeloablative conditioning regimen for allogeneic hematopoietic cell transplantation for the past twenty years. During that period, changes…”
Get full text

Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation by Mielcarek, Marco, Martin, Paul J., Leisenring, Wendy, Flowers, Mary E.D., Maloney, David G., Sandmaier, Brenda M., Maris, Michael B., Storb, Rainer

“…It is unknown whether the severity, timing, and quality of graft-versus-host disease (GVHD) may be different after nonmyeloablative as compared with…”
Get full text

Acute pancreatitis following Pancreaticoduodenectomy: A prospective study of diffusion-weighted magnetic resonance imaging, serum biomarkers, and clinical features by Bannone, Elisa, Marchegiani, G., Zamboni, G., Maris, B., Costa, L., Procida, G., Vacca, P., De-Madaria, E., Salvia, R., Bassi, C.

Get full text

Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities by Sorror, Mohamed L., Maris, Michael B., Storer, Barry, Sandmaier, Brenda M., Diaconescu, Razvan, Flowers, Christopher, Maloney, David G., Storb, Rainer

“…We have carried out HLA-matched unrelated donor hematopoietic cell transplantation (HCT) after nonmyeloablative conditioning in patients with hematologic…”
Get full text

Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning by Fukuda, Takahiro, Boeckh, Michael, Carter, Rachel A., Sandmaier, Brenda M., Maris, Michael B., Maloney, David G., Martin, Paul J., Storb, Rainer F., Marr, Kieren A.

“…The incidence of invasive mold infections has increased during the 1990s among patients undergoing allogeneic hematopoietic stem cell transplantation (HCT)…”
Get full text

Treatment for Acute Myelogenous Leukemia by Low-Dose, Total-Body, Irradiation-Based Conditioning and Hematopoietic Cell Transplantation From Related and Unrelated Donors by HEGENBART, Ute, NIEDERWIESER, Dietger, AL-ALI, Haifa, STORER, Barry, MALONEY, David, MCSWEENEY, Peter, CHAUNCEY, Thomas, AGURA, Ed, BRUNO, Benedetto, MAZIARZ, Richard T, PETERSEN, Finn, STORB, Rainer, SANDMAIER, Brenda M, MARIS, Michael B, SHIZURU, Judith A, GREINIX, Hildegard, CORDONNIER, Catherine, RIO, Bernard, GRATWOHL, Alois, LANGE, Thoralf

“…The use of low-dose, irradiation-based preparative regimens have allowed the extension of allografting to older and medically infirm patients. The study…”
Get full text

Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemia by RAM, Ron, STORB, Rainer, LANGSTON, Amelia A, STORER, Barry, GEORGES, George E, SANDMAIER, Brenda M, MALONEY, David G, WOOLFREY, Ann, FLOWERS, Mary E. D, MARIS, Michael B, LAPORT, Ginna G, CHAUNCEY, Thomas R, LANGE, Thoralf

“…Allogeneic hematopoietic cell transplantation is a potentially curative treatment for patients with acute lymphoblastic leukemia. However, the majority of…”
Get full text

Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma by Maris, Michael B., Sandmaier, Brenda M., Storer, Barry E., Chauncey, Thomas, Stuart, Monic Jain, Maziarz, Richard T., Agura, Edward, Langston, Amelia A., Pulsipher, Michael, Storb, Rainer, Maloney, David G.

“…We carried out HLA-matched related (n = 16) and unrelated (n = 17) hematopoietic cell transplantation (HCT) in 33 patients with relapsed and refractory mantle…”
Get full text

A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia by Lancet, Jeffrey E, Roboz, Gail J, Cripe, Larry D, Michelson, Glenn C, Fox, Judith A, Leavitt, Richard D, Chen, Tianling, Hawtin, Rachael, Craig, Adam R, Ravandi, Farhad, Maris, Michael B, Stuart, Robert K, Karp, Judith E

“…Vosaroxin is a first-in-class anticancer quinolone derivative that intercalates DNA and inhibits topoisomerase II. This study assessed the safety and…”
Get full text

A randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor transplantation by Kornblit, Brian, Maloney, David G, Storer, Barry E, Maris, Michael B, Vindeløv, Lars, Hari, Parameswaran, Langston, Amelia A, Pulsipher, Michael A, Bethge, Wolfgang A, Chauncey, Thomas R, Lange, Thoralf, Petersen, Finn B, Hübel, Kai, Woolfrey, Ann E, Flowers, Mary E D, Storb, Rainer, Sandmaier, Brenda M

“…The study is a randomized phase II trial investigating graft-versus-host disease prophylaxis after non-myeloablative (90 mg/m(2) fludarabine and 2 Gy total…”
Get full text

Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning for Advanced Chronic Lymphocytic Leukemia by SORROR, Mohamed L, MARIS, Michael B, MCSWEENEY, Peter, RADICH, Jerald P, BREDESON, Christopher, BRUNO, Benedetto, LANGSTON, Amelia, LOKEN, Michael R, AL-ALI, Haifa, BLUME, Karl G, STORB, Rainer, MALONEY, David G, SANDMAIER, Brenda M, STORER, Barry E, STUART, Monic J, HEGENBART, Ute, AGURA, Edward, CHAUNCEY, Thomas R, LEIS, Jose, PULSIPHER, Michael

“…Patients with chemotherapy-refractory chronic lymphocytic leukemia (CLL) have a short life expectancy. The aim of this study was to analyze the outcome of…”
Get full text